

Special Issue

Antimicrobial Resistance and Zoonoses

Message from the Guest Editors

Antimicrobial resistance in bacteria with zoonotic potential is of special significance to a correlation between human health, animal health, and the environment underlying the One Health concept. The phenomenon of antimicrobial resistance remains poorly recognized in some important zoonotic pathogens. There is still limited data on resistance phenotypes and mechanisms in zoonotic species belonging to the genera such as *Rickettsia*, *Chlamydia*, *Coxiella*, *Borrelia*, *Leptospira*, *Brucella*, *Francisella*, or *Mycoplasma*. It should be highlighted that those bacteria are frequently multi-host pathogens infecting domestic as well as wild animals. Various factors, including those causing a co-selection effect, may influence such bacteria, leading to development of acquired antimicrobial resistance. In this context, every piece of research on the resistance determinants and every surveillance of their dissemination or every monitoring the spread of resistant strains in different geographical regions, providing new data on the antimicrobial resistance in zoonotic pathogens, is particularly valuable for both human and veterinary medicine.

Guest Editors

Dr. Magdalena Rzewuska

Prof. Dr. Marina Spînu

Dr. Lucjan Witkowski

Deadline for manuscript submissions

closed (31 August 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/78840

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)